John Woolmore

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 337 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +14

Susceptibility and outcome in MS

Jonathan Partridge, S. J. M. Weatherby, John Woolmore et al. · Neurology · 2004 · 90 citations

Life Sciences, Genetics, Neurology +15

Quality of life in multiple sclerosis is dominated by fatigue, disability and self-efficacy

Carolyn Young, Roger Mills, David Rog et al. · Journal of the Neurological Sciences · 2021 · 61 citations

Medicine, Neurology, Disability Management +11

Disability, depression and suicide ideation in people with multiple sclerosis

Vivienne Lewis, K. Williams, C. KoKo et al. · Journal of Affective Disorders · 2016 · 53 citations · Full text

Nursing, Neurology, Psychiatry +14

The unidimensional self-efficacy scale for MS (USE-MS): developing a patient based and patient reported outcome

CA Young, R. J. Mills, John Woolmore et al. · Multiple Sclerosis Journal · 2012 · 40 citations

Social Sciences, Behavioral Sciences, Psychology +16